Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Prelude Therapeutics ( (PRLD) ) is now available.
Prelude Therapeutics said that, under a previously established Open Market Sale Agreement with Jefferies LLC, it has the ability to issue and sell up to $75 million of its common stock. On March 12, 2026, the company filed a prospectus supplement under its existing shelf registration to permit at‑the‑market offerings of up to $25 million in common stock through Jefferies as sales agent, providing additional flexibility to raise equity capital over time.
The filing, made under a shelf registration that became effective on June 10, 2024, allows Prelude to access incremental funding as needed without committing to a single large issuance. This structure may help the company manage dilution while supporting ongoing operational and development needs, and it underscores continued reliance on public equity markets to finance its growth plans.
The most recent analyst rating on (PRLD) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
Score is held back most by weak financial performance (large ongoing losses and cash burn despite improving trends and low leverage). Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and a constructive earnings-call outlook driven by the Incyte partnership and defined 2026 clinical catalysts, while valuation remains difficult to justify with negative earnings and no dividend.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics Incorporated is a biopharmaceutical company focused on developing innovative cancer therapies, with its primary activities centered on discovering and advancing small‑molecule drug candidates. The company accesses U.S. capital markets to fund its research and development programs and related corporate operations through registered equity offerings.
Average Trading Volume: 444,001
Technical Sentiment Signal: Buy
Current Market Cap: $222.9M
Find detailed analytics on PRLD stock on TipRanks’ Stock Analysis page.